Editorial| Volume 143, ISSUE 2, P227-228, November 2016

Download started.


STIC-ing with what we know

  • Lee-may Chen
    Tel.: +1 415 885 7561; fax: +1 415 885 3586.
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, & Reproductive Science, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, 550 16th St. 7th Floor, San Francisco, CA 94158
    Search for articles by this author
      It is time to agree that serous tubal intraepithelial carcinomas (STIC lesions) are cancers, even though the management of occult STIC lesions, whether additional surgical staging or chemotherapy is indicated, remains unclear.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Zakhour M.
        • Danovitch Y.
        • Lester J.
        • et al.
        Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers.
        Gynecol. Oncol. 2016; 143: 231-235
        • Patrono M.G.
        • Iniesta M.D.
        • Malpica A.
        • et al.
        Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review.
        Gynecol. Oncol. 2015; 139 (PMID: 26407480): 568-572
        • Conner J.R.
        • Meserve E.
        • Pizer E.
        • et al.
        Outcome of adnexal neoplasia discovered during risk reducing salpingo-oophrectomy in women with germ-lin BRCA1 or BRCA2 mutations.
        Gynecol. Oncol. 2014; 132: 280-286
        • Wethington S.L.
        • Park K.J.
        • Soslow R.A.
        • et al.
        Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC).
        Int. J. Gynecol. Cancer. 2013; 23 (PMID: 24172097): 1603-1611
        • Powell C.B.
        • Chen L.
        • McLennan J.
        • et al.
        Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers. Experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.
        Int. J. Gynecol. Cancer. 2011; 21 (PMID: 21670699): 846-851
        • Cass I.
        • Walts A.
        • Karlan B.Y.
        Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube?.
        Gynecol. Oncol. 2010; 117 (PMID: 20110118): 27-31
        • Shu C.A.
        • Pike M.C.
        • Jotwani A.R.
        • et al.
        Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations.
        JAMA Oncol. 2016; (Epub ahead of print PMID: 27367496)
      1. G Landon, J Stewart, M Deavers, et al. Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: A 10-year experience and reappraisal of its clinical utility. DOI:, (PMID: 16430946).

        • Prat J.
        • Olawaiye A.B.
        • Bermudez A.
        • et al.
        Amin M.B. Edge S. Greene F.L. Ovary, Fallopian tube, and Primary Peritoneal Carcinomas. AJCC Cancer Staging Manual. 8th edition. Springer International Publishing, 2017
        • Powell C.B.
        • Swisher E.M.
        • Cass I.
        • et al.
        Long term follow-up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk-reducing salpingo-oophorectomy.
        Gynecol. Oncol. 2013; 129 (PMID: 23391663): 364-371
      2. Genetic/Familial High Risk Assessment: Breast and Ovarian. NCCN Guidelines Version 1.2017.